Open Label, Multicenter, Real World Practice of Durvalumab in Lung Cancer (Imfinzi PMS)

Trial Identifier: D4194R00004
Sponsor: AstraZeneca
NCTID:: NCT04068168
Start Date: January 2020
Primary Completion Date: February 2025
Study Completion Date: February 2025
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
South Korea Busan, South Korea
South Korea Chungcheongnam-do, South Korea
South Korea Daegu, South Korea
South Korea Gangwon, South Korea
South Korea Gwangju, South Korea
South Korea Gyeonggi-do, South Korea
South Korea Gyeongsangbuk-do, South Korea
South Korea Gyeongsangnam-do, South Korea
South Korea Incheon, South Korea
South Korea Jeju, South Korea
South Korea Jeollabuk-do, South Korea
South Korea Jeollanam-do, South Korea
South Korea Seoul, South Korea